A group of researchers Massachusetts Institute of Technology (MIT) A new artificial strategy has been developed to incorporate and regenerate a cartilage of arthritis to fight arthritis. Beforehand, testing in rats, is a breakthrough in getting a treatment that slows the progression of a current illness.
Osteoarthritis is a progressive degeneration of the cartilage of joints resulting from aging or injury. This disease affects around 300 million people around the world, and has no reverse, because it is a hundred that can not be recreated by cartilage. Although there are therapies that can reduce the symptoms of osteoarthritis, there is no progress in slowing down progress so far.
One of the difficulties with treatment is that the drug can not easily enter the cartilage. Most seizures are eliminated before the effect or cells that occur when the cartilage does not enter into congenital cells, so they can not perform their functions.
That is why researchers have designed a nano-carrier, a molecule that acts as a vehicle capable of incorporating cartilage and carrying a conducting drug. It forms a spherical component that binds this molecule, and thus connects the drug to the branch structure, with a positive electric charge and the PEG compound.
Since the cartilage is a negative charge, the positive charge of the nantransporter retains the fabric. PEG opens the passage through the cartilage and, thus, the condrocits arrive.
According to the magazine Science Translational MedicineScientists have added a drug called IGF-1 to stimulate nuclease, cartilage production and survival and stimulation of growth of condrocits. To test this experiment, a nanocative after an injury is injected into the joints of the arthritis knee.
This treatment decreased the cartilage degeneration, the appearance of inflammation and bone disorders. Likewise, with a nanotubes, half of the arthritis drug was multiplied ten times. In addition, effective cartilage concentrations have been maintained within thirty days, and therefore, for two months or more, one injection would be sufficient.
"The study is very interesting," says Josep Vergés, president and doctor of the International Exhibition of the International Institute of Research (OAFI).
According to Verges, if it was applied to people and was effective in rats, the quality of life of the patients could be improved, since one or two months would be sufficient. However, it is still necessary to confirm in clinical trials. Thanks to this medicine, it can take four to eight years to be commercially available.